Skip to main content
Fig. 1 | Allergy, Asthma & Clinical Immunology

Fig. 1

From: Immune endotyping and gene expression profile of patients with chronic rhinosinusitis with nasal polyps in the aspirin-exacerbated respiratory disease (AERD) and the non-AERD subgroups

Fig. 1

Results from pulmonary function tests including FEV1 (A), FEV1/FVC (B), and MEF 25–75% (C) showed no significant difference between the AERD and the non-AERD subgroups of CRSwNP both before and after the challenge (#=Comparison between before and after challenge in the AERD and the non-AERD groups). p < 0.05 was considered as significant result (FEV1 = Forced expiratory volume in 1 s, FEV1/FVC = Forced expiratory volume in 1 s/Forced vital capacity, MEF 25–75%= Maximal expiratory flow between 25% and 75% of the FVC, AERD = Aspirin-exacerbated respiratory disease, CRSwNP = Chronic rhinosinusitis with nasal polyp)

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us